Top

Published in:

01-09-2010 | Review Article

Management of Mixed Dementia

Authors: Dr Dina Zekry, Gabriel Gold

Published in: Drugs & Aging | Issue 9/2010

Abstract

Alzheimer’s disease (AD) and vascular dementia (VaD) are the most common causes of dementia in the elderly. Although AD can be diagnosed with a considerable degree of accuracy, the distinction between isolated AD, VaD and mixed dementia (MD) [when both pathologies coexist in the same patient] remains a controversial issue and one of the most difficult diagnostic challenges. MD represents a very common pathology, especially in the elderly, as reported in neuropathological studies. Accurate diagnosis of MD is of crucial significance for epidemiological purposes and for preventive and therapeutic strategies. Until recently, pharmacological studies have generally focused on pure disease, either AD or VaD, and have provided few data on the best therapeutic approach to MD. There is only one original randomized clinical trial on (acetyl)cholinesterase inhibitor therapy (GAL-INT-6, galantamine) for MD; the other studies are post hoc analyses of AD trial subgroups (AD2000, donepezil) or of VaD trial subgroups (VantagE, rivastigmine). Cholinesterase inhibitors have reproducible beneficial effects on cognitive and functional outcomes in patients with MD. These benefits are of a similar magnitude to those previously reported for the treatment of AD. It is likely that the beneficial effects of memantine (an NMDA receptor antagonist) in AD may also apply to MD, but randomized controlled trials are still lacking. Treatment of cardiovascular risk factors, especially hypertension, may protect brain function and should be included in prevention strategies for MD.

Henderson AS, Jorm AF. Definition and epidemiology of dementia: a review. In: Maj M, Sartorius N, editors. Dementia. Chichester: John Wiley & Sons, 2000: 1–68

Hébert R, Brayne C. Epidemiology of vascular dementia. Neuroepidemiology 1995; 14: 240–57PubMed

Kaye JA. Diagnostic challenges in dementia. Neurology 1998; 51: S45–52PubMed

Cummings JL, Benson DF. Dementia: a clinical approach. Boston (MA): Butterworth-Heinemann, 1989

Cohen CI, Araujo L, Guerrier R, et al. “Mixed dementia”: adequate or antiquated? A critical review. Am J Geriatr Psychiatry 1997; 5: 279–83PubMed

Zekry D, Hauw J-J, Gold G. Mixed dementia: epidemiology, diagnosis and treatment. J Am Geriatr Soc 2002; 50: 1431–8PubMed

Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 2002; 109: 813–36PubMed

Gold G, Giannakopoulos P, Herrmann F, et al. Identification of Alzheimer and vascular lesion thresholds for mixed dementia. Brain 2007; 130: 2830–6PubMed

Giannakopoulos P, Gold G, Kovari E, et al. Assessing the cognitive impact of Alzheimer disease pathology and vascular burden in the aging brain: the Geneva experience. Acta Neuropathol 2007; 113: 1–12PubMed

10.

Gold G, Kovari E, Hof PR, et al. Sorting out the clinical consequences of ischemic lesions in brain aging: a clinicopathological approach. J Neurol Sci 2007; 257: 17–22PubMed

11.

Jellinger KA. Neuropathological evaluation of mixed dementia. J Neurol Sci 2007; 257: 80–7PubMed

12.

Zekry D, Duyckaerts C, Moulias R, et al. The vascular lesions in vascular and mixed dementia: the weight of functional neuroanatomy. Neurobiol Aging 2003; 24: 213–9PubMed

13.

Zekry D, Duyckaerts C, Moulias R, et al. Degenerative and vascular lesions of the brain have synergistic effects in dementia of the elderly. Acta Neuropathol 2002; 103: 481–7PubMed

14.

Nyenhuis DL, Gorelick PB. Vascular dementia: a contemporary review of epidemiology, diagnosis, prevention and treatment. J Am Geriatr Soc 1998; 46: 1437–48PubMed

15.

Gold G, Giannakopoulos P, Bouras C. Reevaluating the role of vascular changes in the differential diagnosis of Alzheimer’s disease and vascular dementia. Eur Neurol 1998; 40: 121–9PubMed

16.

Reisberg B, Franssen E, Shah MA, et al. Clinical diagnosis of dementia: a review. In: Maj M, Sartorius N, editors. Dementia. Chichester: John Wiley & Sons, 2000: 69–139

17.

Samuels SC, Davis KL. Pharmacological treatment of dementia: a review. In: Maj M, Sartorius N, editors. Dementia. Chichester: John Wiley & Sons, 2000; 199–268

18.

Gold G, Giannakopoulos P, Bouras C. Vascular dementia. In: Hof P, Mobbs C, editors. Functional neurobiology of aging. San Diego (CA): Academic Press, 2001: 131–43

19.

Knopman DS, Dekosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1143–53PubMed

20.

Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1154–66PubMed

21.

Van Duijn CM, Stijnen T, Hofman A. Risk factors for Alzheimer’s disease: overview of the EURODEM collaborative re-analysis of case-control studies. Int J Epidemiol 1991; 20Suppl. 2: S4–11PubMed

22.

Breteler MB. Vascular risk factors for Alzheimer’s disease: an epidemiologic perspective. Neurobiol of Aging 2000; 21: 153–60

23.

Skoog I. Risk factors for vascular dementia: a review. Dementia 1994; 5: 137–44PubMed

24.

Gorelick PB. Status of risk factors for dementia associated with stroke. Stroke 1997; 28: 459–63PubMed

25.

Gorelick PB, Freels S, Harris Dollear BS, et al. Epidemiology of vascular and Alzheimer’s dementia among African Americans in Chicago, IL. Neurology 1994; 44: 1391–6PubMed

26.

Babikian U. Binswanger’s disease: a review. Stroke 1987; 18: 1–12

27.

Rockwood K, Ebly E, Hachinski V, et al. Presence and treatment of vascular risk factors in patients with vascular cognitive impairment. Arch Neurol 1997; 54: 33–9PubMed

28.

Meyer J, McClintic K, Rogers R, et al. Aetiological considerations and risk factors for multi-infarct dementia. J Neurol Neurosurg Psych 1988; 51: 1489–7

29.

Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141–4PubMed

30.

Skoog I. Status of risk factors for vascular dementia. Neuroepidemiology 1998; 17: 2–9PubMed

31.

Skoog I. The interaction between vascular disorders and Alzheimer’s disease. In: Iqbal K, Swaab DF, Winblad B, et al., editors. Alzheimer’s disease and related disorders: etiology, pathogenesis and therapeutics. Chichester: John Wiley & Sons, 1998: 523–30

32.

Lindsay J, Hebert R, Rockwood K. The Canadian study of health and aging-risk factors for vascular dementia. Stroke 1997; 28: 526–30PubMed

33.

Ueda K, Kawano H, Hasuo Y, et al. Prevalence and etiology of dementia in a Japanese community. Stroke 1992; 23: 798–803PubMed

34.

Kotsoris H, Barclay LL, Kheyferts S, et al. Urinary and gait disturbances as markers for early multi-infarct dementia. J Neurol Neurosurg Psychiatry 1988; 1: 138–41

35.

Ratcliffe PJ, Wilcock CK. Cerebrovascular disease in dementia: the importance of atrial fibrillation. Postgrad Med J 1985; 61: 201–4PubMed

36.

Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347–51PubMed

37.

Skoog I, Kalaria RN, Breteler MM. Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord 1999; 13: S106–14PubMed

38.

Vogel T, Dali-Youcef N, Kaltenbach G, et al. Homocysteine, vitamin B12, folate and cognitive functions: a systematic and critical review of the literature. Int J Clin Pract Int J Clin Pract 2009; 63: 1061–7

39.

Corey-Bloom J, Galasko D, Hofstetter CR, et al. Clinical features distinguishing large cohorts with possible AD, probable AD, and mixed dementia. J Am Geriatr Soc 1993; 41: 31–7PubMed

40.

Rockwood K, Macknight C, Wentzel C, et al. The diagnosis of “mixed dementia” in the Consortium for the Investigation of Vascular Impairment of Cognition (CIVIC). Ann N Y Acad Sci 2000; 903: 522–8PubMed

41.

Whitmer RA, Sidney S, Selby J, et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005; 64: 277–81PubMed

42.

SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3225–64

43.

Staessen JA, Fagard R, Thijs L, et al. Randomized double-blind comparison of placebo and active treatment of older patients with isolated systolic hypertension. Lancet 1997; 350: 757–64PubMed

44.

Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 24: 1347–51

45.

Lithell H, Hansson L, Skoog I, et al., SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–86PubMed

46.

Trenkwalder P. The Study on COgnition and Prognosis in the Elderly (SCOPE): recent analyses. J Hypertens Suppl 2006; 24: S107–14PubMed

47.

Zanchetti A, Elmfeldt D. Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE): a review. Blood Press 2006; 15: 71–9PubMed

48.

in’t Veld BA, Ruitenberg A, Hofman A, et al. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging 2001; 22: 407–12PubMed

49.

Beckett NS, Peters R, Fletcher AE. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887–98PubMed

50.

Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVETCOG): a double-blind, placebo controlled trial. Lancet Neurol 2008; 7: 683–9PubMed

51.

Peters R, Beckett N, Forette F, et al. Vascular risk factors and cognitive function among 3763 participants in the Hypertension in the Very Elderly Trial (HYVET): a cross-sectional analysis. Int Psychogeriatr 2009; 2: 359–68

52.

McGuinness B, Todd S, Passmore P, et al. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev 2009; (4): CD004034

53.

Amarenco P, Bogousslavsky J, et al., Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–59PubMed

54.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22

55.

Shepherd J, Blauw GJ, Murphy MB, et al., PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623–30PubMed

56.

Bernick C, Katz R, Smith NL, et al., Cardiovascular Health Study Collaborative Research Group. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology 2005; 65: 1388–94PubMed

57.

Rea TD, Breitner JC, Psaty BM, et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 2005; 62: 1047–51PubMed

58.

Li G, Higdon R, Kukull WA, et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004; 63: 1624–8PubMed

59.

Zandi PP, Sparks DL, Khachaturian AS, et al., Cache County Study investigators. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 2005; 62: 217–24PubMed

60.

Nelson MR, Reid CM, Ames DA, et al. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Aust 2008; 189: 105–9PubMed

61.

Kivipelto M, Ngandu T, Laatikainen T, et al. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 2006; 5: 735–41PubMed

62.

Tzourio C, Anderson C, Chapman N, et al., PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163: 1069–75PubMed

63.

Dufouil C, Chalmers J, Coskun O, et al., PROGRESS MRI Substudy Investigators. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005; 112: 1644–50PubMed

64.

Grantham C, Geerts H. The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease. J Neurol Sci 2002; 203: 131–6PubMed

65.

Roman G, Kalaria R. Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol Aging 2006; 27: 1769–85PubMed

66.

Saito H, Togashi H, Yoshioka M, et al. Animal models of vascular dementia with emphasis on stroke prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppl 1995; 22: S257–9PubMed

67.

Kimura S, Saito H, Minami M, et al. Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology 2000; 153: 167–78PubMed

68.

Togashi H, Kimura S, Matsumoto M, et al. Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats. Stroke 1996; 27: 520–5PubMed

69.

Togashi H, Matsumoto M, Yoshioka M, et al. Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats. Neurosci Lett 1994; 166: 117–20PubMed

70.

Ferrari R, Frasoldati A, Leo G, et al. Changes in nicotinic acetylcholine receptor subunit mRNAs and nicotinic binding in spontaneously hypertensive stroke prone rats. Neurosci Lett 1999; 277: 169–72PubMed

71.

Gottfries CG, Blennow K, Karlsson I, et al. The neurochemistry of vascular dementia. Dementia 1994; 5: 163–7PubMed

72.

Wallin A, Alafuzoff I, Carlsson A, et al. Neurotransmitter deficits in a nonmulti-infarct category of vascular dementia. Acta Neurol Scand 1989; 79: 397–06PubMed

73.

Tohgi H, Abe T, Kimura M, et al. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J Neural Transm 1996; 103: 1211–20PubMed

74.

Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007; 6: 782–92PubMed

75.

Erkinjuntti T. Galantamine shows efficacy in patients with Alzheimer’s disease with cerebrovascular components or probable vascular dementia [abstract]. Neurology 2001; 56 Suppl.: A340

76.

Erkinjuntti T, Gauthier S, Bullock R, et al. Galantamine treatment in Alzheimer’s disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6). J Psychopharmacol 2008; 7: 761–8

77.

Small G, Erkinjuntti T, Kurz A, et al. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer’s disease with cerebrovascular disease. CNS Drugs 2003; 17: 905–14PubMed

78.

Bullock R, Erkinjuntti T, Lilienfeld S, GAL-INT-6 Study Group. Management of patients with Alzheimer’s disease plus cerebrovascular disease: 12-month treatment with galantamine. Dement Geriatr Cogn Disord 2004; 17: 29–34PubMed

79.

Kumar V, Anand R, Messina J, et al. An efficacy and safety analysis of Exelon® in Alzheimer’s disease patients with concurrent vascular risk factors. Eur J Neurol 2000; 7: 159–69PubMed

80.

Potkin SG, Alva G, Gunay I, et al. A pilot study evaluating the efficacy and safety of rivastigmine in patients with mixed dementia. Drugs Aging 2006; 23: 241–9PubMed

81.

Reisberg B, Schneider L, Doody R, et al. Clinical global measures of dementia: position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997; 11: 8–18PubMed

82.

McKahn G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939–44

83.

Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250–60PubMed

84.

DeJong R, Osterlund OW, Roy GW. Measurement of quality-of-life changes in patients with Alzheimer’s disease. Clin Ther 1989; 11: 545–54PubMed

85.

Kurz A. Galantamine improves cognitive and global abilities in Alzheimer’s disease with cerebrovascular components and probable vascular dementia: preliminary results [abstract]. Neurology 2001; 56 Suppl.: A340

86.

Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283–90PubMed

87.

Rosen W, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141: 1356–64PubMed

88.

Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 1Suppl. 2: S22–32

89.

Gélinas I, Gauthier L, McIntyre M, et al. Development of a functional measure for persons with Alzheimer’s disease: the disability assessment for dementia. Am J Occup Ther 1999; 53: 471–81PubMed

90.

Erkinjuntti T, Kurz A, Small GW, et al. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther 2003; 25: 1765–82PubMed

91.

Kurz AF, Erkinjuntti T, Small GW, et al. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer’s disease with cerebrovascular disease. Eur J Neurol 2003; 10: 633–40PubMed

92.

Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308–14PubMed

93.

Rosen WG, Terry RD, Fuld PA, et al. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980; 7: 486–8PubMed

94.

Erkinjuntti T, Skoog I, Lane R, et al. Rivastigmine in patients with Alzheimer’s disease and concurrent hypertension. Int J Clin Pract 2002; 56: 791–6PubMed

95.

Erkinjuntti T, Skoog I, Lane R, et al. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. Int J Clin Pract 2003; 57: 756–60PubMed

96.

Ballard C, Sauter M, Scheltens P, et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable VaD: the VantagE study. Curr Med Res Opin 2008; 24: 2561–74PubMed

97.

Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105–15PubMed

98.

Obering C, Obering C, Batrash A. Case report: combined use of donepezil and galantamine in mixed dementia. J Am Geriatr Soc 2009; 57: 1934–5PubMed

99.

Shua-Haim J, Smith J, Amin S, et al. Comparison of combination therapy with rivastigmine (Exelon) and donepezil (Aricept) versus rivastigmine alone for treatment of Alzheimer’s disease: safety, tolerability and clinical experience after one year of treatment (a cross-sectional study). Neurobiol Aging 2002; 1: 76–7

100.

Mobius HJ. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003; 348: 1333–41PubMed

101.

Orgogozo JM, Rigaud AS, Stöffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33: 1834–9PubMed

102.

Wilcock G, Mobius HJ, Stoffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002; 17: 297–305PubMed

103.

Kovari E, Gold G, Herrmann FR, et al. Cortical microinfarcts and demyelination affect cognition in cases of high risk of dementia. Neurology 2007; 68: 927–31PubMed

104.

Bastos-Leite AJ, van der Flier WM, van Straaten EC, et al. The contribution of medial temporal lobe atrophy and vascular pathology to cognitive impairment in vascular dementia. Stroke 2007; 38: 3182–5PubMed

105.

Benisty S, Gouw AA, Porcher R, et al., LADIS Study group. Location of lacunar infarcts correlates with cognition in a sample of non-disabled subjects with age-related white-matter changes: the LADIS study. J Neurol Neurosurg Psychiatry 2009; 80: 478–83PubMed

106.

Mungas D, Jagust WJ, Reed BR, et al. MRI predictors of cognition in subcortical ischemic vascular disease and Alzheimer’s disease. Neurology 2001; 57: 2229–35PubMed

107.

Madureira S, Verdelho A, Ferro J, et al., on behalf of the LADIS Study Group. Development of a neuropsychological battery for the Leukoaraiosis and Disability in the Elderly Study (LADIS): experience and baseline data. Neuroepidemiology 2006; 27: 101–16PubMed

108.

Ferris SH. General measures of cognition. Int Psychogeriatr 2003; 15Suppl. 1: 215–7PubMed

109.

Ylikoski R, Jokinen H, Andersen P, et al., LADIS Study Group. Comparison of the Alzheimer’s Disease Assessment Scale Cognitive Subscale and the Vascular Dementia Assessment Scale in differentiating elderly individuals with different degrees of white matter changes. The LADIS Study. Dement Geriatr Cogn Disord 2007; 24: 73–81PubMed

110.

Langa KM, Foster NL, Larson EB. Mixed dementia: emerging concepts and therapeutic implications. JAMA 2004; 292: 2901–8PubMed

Title: Management of Mixed Dementia
Authors: Dr Dina Zekry
Gabriel Gold
Publication date: 01-09-2010
Publisher: Springer International Publishing
Published in: Drugs & Aging / Issue 9/2010
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.2165/11538250-000000000-00000

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Management of Mixed Dementia

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2010

Potentially Inappropriate Drug Prescriptions and Risk of Hospitalization among Older, Italian, Nursing Home Residents

Metronomic Chemotherapy for Metastatic Prostate Cancer

Risk of Potential Drug-Drug Interactions among Brazilian Elderly

Spotlight on Strontium Ranelate

Pharmacological Therapies for Osteoarthritis of the Hand

Vulnerable Elderly Patients and Overactive Bladder Syndrome

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page